Preventative healthcare startup Everlab has raised $65 million in a Series A as it looks to expand into the UK.
The round was Airtree Ventures, with support from UK fund Plural and Europe’s b2venture and existing investor Left Lane Capital, plus angel investors including Australian test captain Pat Cummins.
Everlab previously raised $3 million in a pre-Seed round in December 2023 before launching publicly the following month. Other investors include Afterwork Ventures, Ten13, AfterWork, Flying Fox and the founders of Go1, and Aconex, and Temedica.
A $15 million Seed round, led by Left Lane, was raised in July 2025.
The three-year-old Melbourne startup, which has analysed more than 20,000 clients in Australia and New Zealand, where it launched last month, delivers preventative AI-enhanced healthcare advice based on advanced biomarker diagnostics to detect and prevent disease.
Extensive testing
A basic health check costs $299, with a range of tests costs between $249 for a genetics test to $3499 for an MRI body scan. Packaged assessments cost between $900 and $2700
Everlab says more than 25% of clients have had health issues that otherwise have gone undetected spotted during its testing, which has been used in executive programs for the likes of Boston Consulting Group, BHP and Bain & Compa
Alongside the UK rollout, the funds will go towards additional clinical and technology infrastructure.
Everlab’s digital app organises diagnostics, doctors, specialists, prescriptions and continuous AI care in one place.
The platform integrates with 1,850+ health provider locations, 180+ active clinicians and 30+ wearable devices, and processes more than 200,000 health reports per month.
Cofounder and CEO Marc Hermann, previously cofounded Foodspring, which was acquired by Mars in 2019, said the existing health system was fragmented, making it harder for patients.
“We built Everlab to hold the full picture, surface health blind spots and coordinate what needs to happen next—from targeted screenings to personalised health plans—helping more people live longer, healthier lives,” he said.
Airtree partner John Henderson said the more time we spent with the Everlab team, the more they were convinced it would become a generational health business.
“With a world-class product and growing at a pace we rarely see, they’re already the leader in Australia and we’re backing them to do the same globally,” he said.
